MedTrace Logo

The Effect of Montelukast in Patients With Chronic Cough and Bronchial Hyperreactivity

NCT00453765 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2013-04-08

No results posted yet for this study

Summary

The purpose is to determine whether montelukast during 6 weeks has superior antitussive effects (measured with the LCQ) compared with placebo in patients with cough lasting \> 8 weeks and enhanced bronchial hyperreactivity.

Conditions

  • Cough
  • Bronchial Hyperreactivity

Interventions

DRUG

montelukast

montelukast, 8 weeks, once daily, 10 milligrams

DRUG

placebo

placebo

Sponsors & Collaborators

  • Isala

    lead OTHER

Principal Investigators

  • Jan Willem Van Den Berg, MD · Departement of Pulmonology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00453765 on ClinicalTrials.gov